THAR (Tharimmune) Dividends per Share : $0.00 (TTM As of Sep. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Tharimmune Dividends per Share?

Tharimmune's dividends per share for the three months ended in Sep. 2024 was $0.00. Its dividends per share for the trailing twelve months (TTM) ended in Sep. 2024 was $0.00. Its Dividend Payout Ratio for the three months ended in Sep. 2024 was 0.00. As of today, Tharimmune's Dividend Yield % is 0.00%.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

For more information regarding to dividend, please check our Dividend Page.

* Please note that "special dividend" is not included in the calculation of dividend per share and related fields.

Tharimmune Dividends per Share Historical Data

The historical data trend for Tharimmune's Dividends per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tharimmune Dividends per Share Chart

Tharimmune Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Dividends per Share

Tharimmune Quarterly Data
	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Dividends per Share	Get a 7-Day Free Trial														-	-	-	-	-

Competitive Comparison of Tharimmune's Dividends per Share

For the Biotechnology subindustry, Tharimmune's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Tharimmune's Dividend Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tharimmune's Dividend Yield % distribution charts can be found below:

* The bar in red indicates where Tharimmune's Dividend Yield % falls into.

Tharimmune Dividends per Share Calculation

Dividends paid to per common share.

Tharimmune (NAS:THAR) Dividends per Share Explanation

1. Dividend Payout Ratio measures the percentage of the company's earnings paid out as dividends.

Tharimmune's Dividend Payout Ratio for the quarter that ended in Sep. 2024 is calculated as

Dividend Payout Ratio	=	Dividends per Share (Q: Sep. 2024 )	/	EPS without NRI (Q: Sep. 2024 )
	=	0	/	-2.45
	=	N/A

2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.

Tharimmune Dividends per Share Related Terms

Thank you for viewing the detailed overview of Tharimmune's Dividends per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Tharimmune Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tharimmune Inc (NAS:THAR) » Definitions » Dividends per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

1200 Route 22 East, Suite 2000, Bridgewater, NJ, USA, 08807

Website

https://www.hillstreambio.com

Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset, known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting epitopes with novel mechanisms of action against validated targets in multiple solid tumors.

Executives

Sireesh Appajosyula	director	1200 ROUTE 22 EAST, SUITE 2000, BRIDGEWATER NJ 08807
Randy Milby	director, officer: Chief Executive Officer	5 JACK LANE, NEWARK DE 19711
Kelly Anderson	director	C/O TOMI ENVIRONMENTAL SOLUTIONS, INC., 9454 WILSHIRE BLVD., R-1, BEVERLY HILLS CA 90212
Leonard L Mazur	director	C/O CITIUS PHARMACEUTICALS, INC., 11 COMMERCE DRIVE, 1ST FLOOR, CRANFORD NJ 07016
Sandeep Laumas	10 percent owner	8480 HONEYCUTT RD, SUITE 200, RALEIGH NC 27615
Thomas Hess	officer: Chief Financial Officer	366 MADISON AVE. 12TH FLOOR, NEW YORK NY 10017
Lynne A. Bui	director	1200 ROUTE 22 EAST, SUITE 2000, BRIDGEWATER NJ 08807
Surender Kharbanda	10 percent owner	1200 ROUTE 22 EAST, SUITE 2000, BRIDGEWATER NJ 08807
Highpoint Pharmaceuticals Llc	10 percent owner	16192 COASTAL HIGHWAY, LEWES DE 19958
Kufe Llc	10 percent owner	179 GROVE STREET, WELLESLEY MA 02482
Varinder Kaur	10 percent owner	1200 ROUTE 22 EAST, SUITE 2000, BRIDGEWATER NJ 08807